{"denoms":[{"counts":[{"groupId":"BG000","value":"351"},{"groupId":"BG001","value":"307"},{"groupId":"BG002","value":"352"},{"groupId":"BG003","value":"1010"}],"units":"Participants"}],"groups":[{"description":"Participants received pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for a maximum of 35 doses PLUS standard therapy (ST) chemotherapy with EITHER cisplatin 70 mg/m\\^2 IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine IV infusion 1,000 mg/m\\^2 on Day 1 and Day 8 of each 3-week cycle, OR carboplatin at an area under the curve 5 (AUC 5) (or AUC 4.5 if required per local guidelines) IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine 1,000 mg/m\\^2 IV on Day 1 and Day 8 of each 3-week cycle. Eligible participants who stopped pembrolizumab with Stable Disease (SD) or better but progressed after discontinuation may have been able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.","id":"BG000","title":"Pembrolizumab + ST Chemotherapy (Pembro Combo)"},{"description":"Participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle for a maximum of 35 doses. Eligible participants who stopped pembrolizumab with SD or better but progressed after discontinuation may have been able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.","id":"BG001","title":"Pembrolizumab (Pembro)"},{"description":"Participants received ST chemotherapy with EITHER cisplatin 70 mg/m\\^2 IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle plus gemcitabine IV infusion 1,000 mg/m\\^2 on Day 1 and Day 8 of each 3-week cycle OR carboplatin at AUC 5 (or AUC 4.5 if required per local guidelines) IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle plus gemcitabine 1,000 mg/m\\^2 IV on Day 1 and Day 8 of each 3-week cycle.","id":"BG002","title":"ST Chemotherapy (Chemo)"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.2","value":"68.3"},{"groupId":"BG001","spread":"10.1","value":"67.0"},{"groupId":"BG002","spread":"9.6","value":"68.0"},{"groupId":"BG003","spread":"9.6","value":"67.8"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"79"},{"groupId":"BG001","value":"79"},{"groupId":"BG002","value":"90"},{"groupId":"BG003","value":"248"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"272"},{"groupId":"BG001","value":"228"},{"groupId":"BG002","value":"262"},{"groupId":"BG003","value":"762"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"32"},{"groupId":"BG003","value":"83"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"269"},{"groupId":"BG001","value":"231"},{"groupId":"BG002","value":"261"},{"groupId":"BG003","value":"761"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"51"},{"groupId":"BG002","value":"59"},{"groupId":"BG003","value":"166"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"47"},{"groupId":"BG002","value":"70"},{"groupId":"BG003","value":"181"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"8"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"243"},{"groupId":"BG001","value":"212"},{"groupId":"BG002","value":"235"},{"groupId":"BG003","value":"690"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"4"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"42"},{"groupId":"BG003","value":"126"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"192"},{"groupId":"BG001","value":"148"},{"groupId":"BG002","value":"193"},{"groupId":"BG003","value":"533"}]}],"title":"PD-L1 CPS<10"},{"categories":[{"measurements":[{"groupId":"BG000","value":"159"},{"groupId":"BG001","value":"159"},{"groupId":"BG002","value":"159"},{"groupId":"BG003","value":"477"}]}],"title":"PD-L1 CPS≥10"}],"description":"The Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) Status indicates tumor PD-L1 positivity using both tumor cells and inflammatory cells that are positive for PD-L1 by immunohistochemistry (IHC). Higher percentages of PD-L1 CPS staining corresponded to higher positivity of PD-L1 on a tumor. The number of participants with CPS \\<10% and CPS ≥10% at baseline randomization by Interactive Voice Response System (IVRS) is presented","paramType":"COUNT_OF_PARTICIPANTS","title":"PD-L1 CPS Status-IVRS","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"160"},{"groupId":"BG001","value":"138"},{"groupId":"BG002","value":"160"},{"groupId":"BG003","value":"458"}]}],"title":"Cisplatin"},{"categories":[{"measurements":[{"groupId":"BG000","value":"191"},{"groupId":"BG001","value":"169"},{"groupId":"BG002","value":"192"},{"groupId":"BG003","value":"552"}]}],"title":"Carboplatin"}],"description":"The Investigator's choice of chemotherapy drug (cisplatin or carboplatin) at baseline randomization by IVRS is presented.","paramType":"COUNT_OF_PARTICIPANTS","title":"Investigator Choice of Cisplatin or Carboplatin - IVRS","unitOfMeasure":"Participants"}]}